Clinical Trial: Utidelone Capsule Combined with Capecitabine and Oxaliplatin in First-line Treatment of PD-L1-negative Gastric or Gastroesophageal Junction Adenocarcinoma Patients

U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06841679) titled 'Utidelone Capsule Combined with Capecitabine and Oxaliplatin in First-line Treatment of PD-L1-negative Gastric or Gastroesophageal Junction Adenocarcinoma Patients' on Feb. 10.

Brief Summary: This is a multi-national, open-label, randomized, seamless phase II/III clinical study of UTD2 combined with capecitabine and oxaliplatin to evaluate the efficacy and safety in patients with PD-L1-negative locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma untreated with systemic treatment in advanced setting.

Study Start Date: May 01, 2025

Study Type: INTERVENTIONAL

Condition: Gastric or Gastroesophageal Jun...